Drug
Ricolinostat clinical trials
Also written ACY-1215.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
10 studies that test it; most in 2014 (3)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2014 | 3 |
| 2016 | 1 |
| 2017 | 1 |
| 2020 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 3
Celgene (3) · Beijing 3E-Regenacy Pharmaceuticals Co., Ltd. (2) · Regenacy Pharmaceuticals LLC (1) · Columbia University (1) · Acetylon Pharmaceuticals Incorporated (1) · Jennifer Amengual (1) · Mayo Clinic (1)
Often tested with
Tested in the same studies.
Lenalidomide (1) · Dexamethasone (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Cisplatin (1) · Gemcitabine (1)
Studies
Open first, then newest update. How each study uses ricolinostat is read from its arms, and is right about nine times in ten.
Testing it · 10
- ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple MyelomaTerminatedPhase 1/2CelgeneNCT01997840Written as ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
- ACY-1215 for Relapsed/Refractory Lymphoid MalignanciesTerminatedPhase 1/2Jennifer AmengualNCT02091063Written as ACY-1215
- A Study to Investigate the Safety and Efficacy of RicolinostatCompletedPhase 1Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.NCT05229042Written as Ricolinostat
- Ricolinostat in Patients With Painful Diabetic Peripheral NeuropathyCompletedPhase 2Regenacy Pharmaceuticals LLCNCT03176472Written as ricolinostat
- Evaluate the Safety and Pharmacokinetics of RicolinostatCompletedPhase 1Beijing 3E-Regenacy Pharmaceuticals Co., Ltd.NCT05193851Written as ricolinostat
- Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple MyelomaCompletedPhase 1CelgeneNCT01583283Written as ACY-1215
- ACY-1215 + Nab-paclitaxel in Metastatic Breast CancerCompletedPhase 1Columbia UniversityNCT02632071Written as ACY-1215
- Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic CholangiocarcinomaWithdrawnPhase 1Mayo ClinicNCT02856568Written as Ricolinostat
- Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple MyelomaCompletedPhase 1/2CelgeneNCT01323751Written as ACY-1215
- Alternative 10 mg/mL Liquid Formulation of ACY 1215 (Ricolinostat) in Healthy SubjectsCompletedPhase 1Acetylon Pharmaceuticals IncorporatedNCT02088398Written as ACY-1215
Given in every arm · 2 — ricolinostat is usual care beside what is tested
- ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLLActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT02787369Written as ACY-1215
- A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological CancerTerminatedPhase 1Dana-Farber Cancer InstituteNCT02661815Written as Ricolinostat
Codes
What other systems call ricolinostat · ClinicalTrials.gg INT006061
- MeSH (NLM) C572255ricolinostatConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) WKT909C62BRICOLINOSTATConfirmed FDA, NLM, Wikidata
- Wikidata Q27088553ricolinostatConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C96431RicolinostatOne source FDA
- DrugBank DB12376One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C572255 | ricolinostat | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | WKT909C62B | RICOLINOSTAT | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27088553 | ricolinostat | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C96431 | Ricolinostat | One source FDA |
| DrugBank | DB12376 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.